These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 30456904)

  • 1. Urinary glucose excretion after dapagliflozin treatment: An exposure-response modelling comparison between Japanese and non-Japanese patients diagnosed with type 1 diabetes mellitus.
    Sokolov V; Yakovleva T; Ueda S; Parkinson J; Boulton DW; Penland RC; Tang W
    Diabetes Obes Metab; 2019 Apr; 21(4):829-836. PubMed ID: 30456904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of pharmacokinetics and the exposure-response relationship of dapagliflozin between adolescent/young adult and adult patients with type 1 diabetes mellitus.
    Busse D; Tang W; Scheerer M; Danne T; Biester T; Sokolov V; Boulton D; Parkinson J
    Br J Clin Pharmacol; 2019 Aug; 85(8):1820-1828. PubMed ID: 31077437
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the pharmacokinetics and pharmacodynamics of dapagliflozin in patients with type 1 versus type 2 diabetes mellitus.
    Tang W; Leil TA; Johnsson E; Boulton DW; LaCreta F
    Diabetes Obes Metab; 2016 Mar; 18(3):236-40. PubMed ID: 26510924
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of dapagliflozin in combination with insulin in Japanese patients with type 1 diabetes.
    Watada H; Shiramoto M; Ueda S; Tang W; Asano M; Thorén F; Kim H; Yajima T; Boulton DW; Araki E
    Diabetes Obes Metab; 2019 Apr; 21(4):876-882. PubMed ID: 30499157
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dapagliflozin in patients with type 1 diabetes: A post hoc analysis of the effect of insulin dose adjustments on 24-hour continuously monitored mean glucose and fasting β-hydroxybutyrate levels in a phase IIa pilot study.
    Henry RR; Dandona P; Pettus J; Mudaliar S; Xu J; Hansen L
    Diabetes Obes Metab; 2017 Jun; 19(6):814-821. PubMed ID: 28098426
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based characterization of the relationship between dapagliflozin systemic exposure and HbA1c response in patients with type 1 diabetes mellitus.
    Parkinson J; Tang W; Åstrand M; Melin J; Ekholm E; Hamrén B; Boulton DW
    Diabetes Obes Metab; 2019 Jun; 21(6):1381-1387. PubMed ID: 30756462
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Empagliflozin as adjunct to insulin in Japanese participants with type 1 diabetes: Results of a 4-week, double-blind, randomized, placebo-controlled phase 2 trial.
    Shimada A; Hanafusa T; Yasui A; Lee G; Taneda Y; Sarashina A; Shiki K; George J; Soleymanlou N; Marquard J
    Diabetes Obes Metab; 2018 Sep; 20(9):2190-2199. PubMed ID: 29766633
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of the exposure-response relationship of dapagliflozin in adult and paediatric patients with type 2 diabetes mellitus.
    Parkinson J; Tang W; Johansson CC; Boulton DW; Hamrén B
    Diabetes Obes Metab; 2016 Jul; 18(7):685-92. PubMed ID: 27299483
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population Pharmacokinetic- Pharmacodynamic Analysis to Characterize the Effect of Empagliflozin on Renal Glucose Threshold in Patients With Type 1 Diabetes Mellitus.
    Mondick J; Riggs M; Kaspers S; Soleymanlou N; Marquard J; Nock V
    J Clin Pharmacol; 2018 May; 58(5):640-649. PubMed ID: 29251772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dapagliflozin Pharmacokinetics Is Similar in Adults With Type 1 and Type 2 Diabetes Mellitus.
    Melin J; Tang W; Rekić D; Hamrén B; Penland RC; Boulton DW; Parkinson J
    J Clin Pharmacol; 2022 Oct; 62(10):1227-1235. PubMed ID: 35403243
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetic and pharmacodynamic properties of single- and multiple-dose of dapagliflozin, a selective inhibitor of SGLT2, in healthy Chinese subjects.
    Yang L; Li H; Li H; Bui A; Chang M; Liu X; Kasichayanula S; Griffen SC; Lacreta FP; Boulton DW
    Clin Ther; 2013 Aug; 35(8):1211-1222.e2. PubMed ID: 23910664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dapagliflozin in patients with type 2 diabetes receiving high doses of insulin: efficacy and safety over 2 years.
    Wilding JP; Woo V; Rohwedder K; Sugg J; Parikh S;
    Diabetes Obes Metab; 2014 Feb; 16(2):124-36. PubMed ID: 23911013
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dapagliflozin for the treatment of type 1 diabetes mellitus.
    Pafili K; Maltezos E; Papanas N
    Expert Opin Investig Drugs; 2017 Jul; 26(7):873-881. PubMed ID: 28587531
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
    Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
    Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of dapagliflozin as an adjunct to insulin over 52 weeks in individuals with type 1 diabetes: post-hoc renal analysis of the DEPICT randomised controlled trials.
    Groop PH; Dandona P; Phillip M; Gillard P; Edelman S; Jendle J; Xu J; Scheerer MF; Thoren F; Iqbal N; Repetto E; Mathieu C
    Lancet Diabetes Endocrinol; 2020 Oct; 8(10):845-854. PubMed ID: 32946821
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus.
    Kasichayanula S; Liu X; Pe Benito M; Yao M; Pfister M; LaCreta FP; Humphreys WG; Boulton DW
    Br J Clin Pharmacol; 2013 Sep; 76(3):432-44. PubMed ID: 23210765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Empagliflozin as adjunct to insulin in patients with type 1 diabetes: a 4-week, randomized, placebo-controlled trial (EASE-1).
    Pieber TR; Famulla S; Eilbracht J; Cescutti J; Soleymanlou N; Johansen OE; Woerle HJ; Broedl UC; Kaspers S
    Diabetes Obes Metab; 2015 Oct; 17(10):928-35. PubMed ID: 26080652
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and safety of dapagliflozin over 1 year as add-on to insulin therapy in Japanese patients with type 2 diabetes: the DAISY (Dapagliflozin Added to patients under InSulin therapY) trial.
    Araki E; Onishi Y; Asano M; Kim H; Yajima T
    Diabetes Obes Metab; 2017 Apr; 19(4):562-570. PubMed ID: 27987240
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dapagliflozin: A Review in Type 1 Diabetes.
    Paik J; Blair HA
    Drugs; 2019 Nov; 79(17):1877-1884. PubMed ID: 31664708
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.